Cost–utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β₂-agonists in South Korea

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [Internet] [updated 2018; cited 2019 Feb 21]. Available from: https://ginasthma.org
   Google Scholar
• Peters SP, Ferguson G, Deniz Y, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100:1139–1151.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Schatz M, Hsu J-W, Zeiger RS, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2014;133:1549–1556.
   PubMed Web of Science ®Google Scholar
• Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol. 2000;106:1033–1042.
   PubMedGoogle Scholar
• Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19:977.
   PubMed Web of Science ®Google Scholar
• Coumou H, Bel EH. Improving the diagnosis of eosinophilic asthma. Expert Rev Resp Med. 2016;10:1093–1103.
   PubMed Web of Science ®Google Scholar
• de Groot JC, ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:00024-2015.
   PubMedGoogle Scholar
• Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR). Respir Med. 2014;108:1723–1732.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics . J Allergy Clin Immunol. 2003;111:714–719.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Resp Med. 2015;3:355–366.
   PubMed Web of Science ®Google Scholar
• Health Insurance Review & Assessment Service. Detailed evaluation standard for drugs to be negotiated [in Korean] [cited 2017 Aug 18]. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=6201#none
   Google Scholar
• Ock M, Jo M-W, Gong Y-h, et al. Estimating the severity distribution of disease in South Korea using EQ-5D-3L: a cross-sectional study. BMC Public Health. 2016;16:234.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Resp J. 2007;16:22.
   PubMedGoogle Scholar
• Lee YJ, Kwon S-H, Hong S-H, et al. Health care utilization and direct costs in mild, moderate, and severe adult asthma: a descriptive study using the 2014 South Korean Health Insurance Database. Clin Ther. 2017;39:527–536.
   PubMed Web of Science ®Google Scholar
• Willson J, Bateman ED, Pavord I, et al. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl Health Econ Health Policy. 2014;12:447–459.
   PubMedGoogle Scholar
• Kang EJ, Kim NY, Park MH, et al. The Third Korea National Health and Nutrition Examination Survey (KNHANES III), 2005: activity limitation and health-related quality of life. Seoul (South Korea): Korea Institute for Health and Social Affairs; 2006. Korean.
   Google Scholar
• Seo NK, Kang TW, Kim NS, et al. A report on the Korea health panel survey of 2014 I. Seoul (South Korea): Korea Institute for Health and Social Affairs; 2016. Korean.
   Google Scholar
• Health Insurance Review & Assessment Service. The Weighted Price of Drug by Component in the First Half Year of 2017. Wonju (South Korea): Health Insurance Review & Assessment Service; 2017.
   Google Scholar
• Health Insurance Review & Assessment Service. Medical/dental service fee. Wonju (South Korea): Health Insurance Review & Assessment Service; 2017.
   Google Scholar
• Korean Statistical Information Service. Life tables [Internet] [Korean] [cited 2018 Jan 25]. Available from: http://www.kosis.kr
   Google Scholar
• Kwon S-S, Kim M-H, Cho Y-J. Factors associated with mortality after asthma admission in the intensive care unit of a tertiary referral hospital. Allergy Asthma Respir Dis. 2015;3:432–438.
   Web of Science ®Google Scholar
• Park H-S, Kim M-K, Imai N, et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169:135–145.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Single Technology Appraisal. Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids [ID872] [Internet] [cited 2017 Aug 21]. Available from: https://www.nice.org.uk/guidance/ta479/history
   Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. OUP Oxford; 2006.
   Google Scholar
• Briggs AH, Ades A, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making. 2003;23:341–350.
   PubMed Web of Science ®Google Scholar
• Yim E-Y, Lim SH, Oh M-J, et al. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea. Value Health. 2012;15:S104–S110.
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. OECD Data. Gross domestic product (GDP) [Internet] [cited 2018 Jun 10]. Available from: https://data.oecd.org/gdp/gross-domestic-product-gdp.htm
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Reslizumab. Common Drug Review. Clinical Pharmacoeconomic Report [Internet] [cited 2017 Jun 20]. Available from: https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0495_Cinqair_PE_Report.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Reslizumab for treating severe eosinophilic asthma. Information for the Public [Internet] [cited 2018 Jun 15]. Available from: https://www.nice.org.uk/guidance/ta479/informationforpublic
   Google Scholar
• Cooper K, Frampton G, Harris P, et al. Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: an evidence review group perspective of a nice single technology appraisal. Pharmacoeconomics. 2018;36:545–553.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee final recommendation. Reslizumab [Internet] [cited 2018 Jun 15]. Available from: https://www.cadth.ca/sites/default/files/cdr/complete/SR0495_complete_Cinqair-Mar-24-17.pdf
   Google Scholar
• Global Asthma Network. The Global Asthma Report [Internet]. 2014 [cited 2018 Jun 18]. Available from: http://www.globalasthmareport.org/burden/mortality.php
   Google Scholar
• Organisation for Economic Co-operation and Development. Health at a Glance 2017: OECD Indicators [Internet] [cited 2018 Jun 15]. Available from: https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2017/avoidable-hospital-admissions_health_glance-2017-31-en
   Google Scholar